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ness of azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treat-
ment of CAP for immunocompetent individuals age 65 and older from the private
healthcare perspective in Brazil.METHODS: A decision-tree model, built based on
the following health states: death, cure and discontinuing due to adverse events
(phlebitis, diarrhea, infusion reaction which would lead to switching the antibiot-
ics). Risks and length of treatment were obtained from the literature and prices
were retrieved from the Brazilian Hierarchic Classification of Medical Procedures
(CBHPM 4th edition - 2005) and public databases. Resource Utilization (exams,
procedures andmaterials) were gathered based on the latest clinical guidelines for
CAP defined by the Brazilian Society of Pneumology. The time horizon was defined
as one year. Effectiveness was expressed as life years gained (LYG). Values were
expressed in 2011 USD. First order probabilistic sensitivity analysis was carried by
Monte Carlo simulation of 10,000 iterations considering the range of values for the
lengths of treatment in a normal distribution. RESULTS: The simulation consider-
ing 10,000 iterations showed the following values for azithromycin and clarithro-
mycin respectively: Total LYG [9,640 vs. 8,840]; average costs per treatment
[USD863.76 vs. USD1,384.15]; average cost-effectiveness ratio [USD896.04/LYG vs.
USD1,566.18/LYG], representing a cost saving of USD 670.14/LYG for azithromycin.
Considering 100,000 cases of pneumonia hospitalizations for adults age 65, the total
savings for the incorporationofazithromycinwouldbeapproximatelyUSD52.072.571.
CONCLUSIONS: In this analysis, azithromycin presented the greatest effectiveness
diminishing costs, by reducing mortality and treatment discontinuation due to
adverse events, from the Brazilian private health care system’s perspective.
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TREATMENTS FOR COMMUNITY ACQUIRED PNEUMONIA REQUIRING
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OBJECTIVES: According to Brazilian public databases (DATASUS), community ac-
quired pneumonia (CAP) requiring hospitalization for individuals of age 65 have a
mortality relative risk increase of 4.05 when compared to the average rate of
younger ages. This study has the objective of evaluating the cost-effectiveness of
azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treatment of
CAP for immunocompetent individuals age 65 and older from the public healthcare
perspective in Brazil.METHODS: A decision-tree model, built based on the follow-
ing health states: death, cure and discontinuing due to adverse events (phlebitis,
diarrhea, infusion reaction which would lead to switching the antibiotics). Risks
and length of treatment were obtained from the published literature and acquisi-
tion costs were retrieved from Brazilian public databases (Banco de Preços em
Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de Procedimentos, Me-
dicamentos e OPMdo SUS). Resource utilization (exams, procedures andmaterials)
were gathered based on the latest clinical guidelines for CAP defined by the Brazil-
ian Society of Pneumology. The timehorizonwas defined as one year. Effectiveness
was expressed as life years gained (LYG). Values were expressed in 2011 USD. First
order probabilistic sensitivity analysis was carried by Monte Carlo simulation of
10,000 iterations considering the range of values for the lengths of treatment in a
normal distribution. RESULTS: Simulation considering 10,000 iterations showed
the following values for azithromycin and clarithromycin respectively: Total LYG
[9,640vs.8,840]; average costs per treatment [USD614.11vs.USD618.15]; average
cost-effectiveness ratio [USD637.07/LYGvs.USD699.23/LYG], representing a cost
saving per patient of USD62.17/LYG for azithromycin. Considering 180,851 cases of
pneumonia hospitalizations for adults age 65 registered at public hospitals in
Brazil(2010), the overall estimated savings for the incorporation of azithromycin
would be approximately USD730,561.15. CONCLUSIONS: In this analysis, azithro-
mycin presented the greatest effectiveness diminishing costs, by reducing mortal-
ity and treatment discontinuation due to adverse events.
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OBJECTIVES: To estimate the economic burden associated with acute exacerba-
tions of chronic obstructive pulmonary disease (COPD) in Tianjin, China.
METHODS: Data from the Tianjin Urban Employee Basic Medical Insurance
(UEBMI) database (2003-2007), including inpatient claims for medical services and
prescription drugs from 30% random sample of enrollees, were used. Acute exac-
erbationwas defined as aCOPDepisode leading to hospitalization. Hospitalizations
of adult patientswith primary diagnosis of COPDanddischarge dates between 2003
and 2007 were selected and the latest COPD hospitalization for each patient was
selected to estimate healthcare utilization and costs associated with COPD acute
exacerbation. All costs were estimated in 2007 U.S. dollars using the Medical Ser-
vice Consumer Price Index (CPI) in China and an exchange rate of 7.598 Chinese
Yuan to 1 USD in 2007. RESULTS: A total of 1321 COPD patients with acute exacer-
bations were identified, with a mean age of 71.1 years and 41.3% female. Approxi-
mately 38.4% of all patients had at least one complication, 21.3% had cor pulmo-
nale, 19.8% had pneumonia, 11.0% had congestive heart failure, and 4.9% had
bronchiectasis. About 58.2% hospitalizations occurred in tier-3 hospitals, 36.2% in
tier-2 hospitals and 5.6% in tier-1 hospitals. The mean length of stay was 16.8 days
per hospitalization. About 92.9% patients received antiathmatic, 75.2% received
expectorant, and 24.6% received antitussive during hospitalization. Themean total
cost per acute exacerbation/hospitalization was $1323 with 74.1% covered by
UEBMI and 25.9% by patients. Medication costs accounted for 56.3% of the total
inpatient costs. Examination costs and bed costs accounted for 16.4% and 4.5%,
respectively. CONCLUSIONS: Complications of COPD are common among patients
with COPD exacerbations. The majority of patients with COPD exacerbations are
treated in tier-3 hospitals. COPD exacerbations incur high health care utilization
and costs. Medication costs account for the majority of the costs associated with
exacerbations.
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OBJECTIVES: To estimate the national prevalence and the direct incremental costs
of Chronic Obstructive Pulmonary Disease (COPD) and asthma using the 2007Med-
ical Expenditure Panel Survey (MEPS) data. METHODS: This was a retrospective
study of patient records identified using ICD-9-CM diagnosis and procedure codes
for principal diagnosis of COPD (491.0, 492.0, 496.0) and asthma (493.0, 493.1, 493.2)
from the 2007 MEPS data. The main independent variable was the presence or
absence of either COPD or asthma. Age, gender, race, income, insurance status,
marital status and region were selected as covariates. The dependent variables
were total health care, office-based, outpatient, inpatient, emergency room, and
prescription expenditures. Descriptive statistics and regression analyses were uti-
lized to generate prevalence data, total mean health care expenditures, and signif-
icant predictors for individuals with COPD and asthma. RESULTS: The national
prevalence of COPD and asthma in 2007 was estimated at 1.3 million and 28.3
million, respectively. Among individuals with COPD, the estimated total direct
incremental health care expenditures per person was $1739.27 with a national
estimate of $2.2 billion. Among individuals with asthma, the estimated total direct
incremental health care expenditure per person was $2133.83 with a national es-
timate of $60 billion. The largest cost category for COPD was office-based expendi-
tures ($610.55) followed by prescription expenditures ($347.88). For asthma, the
largest cost categories were prescription expenditures ($760.72) followed by inpa-
tient expenditures ($617.23). Age, gender, region, insurance and marital status
were significant predictors for health care expenditures in COPD and asthma.
CONCLUSIONS: This study highlights the socio-demographic disparities in terms
of prevalence and provides national estimates on health care expenditures among
individuals with COPD and asthma. These estimates can serve as a guide for policy
makers in the formulation of health care policies on screening, treatment guide-
lines, and identification of high-risk population for COPD and asthma.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading
cause of death in the world and remains a disease with substantial residual mor-
bidity and cost burden. Current evidence-based guidelines focus attention on
achieving and maintaining disease stability and reducing the incidence of exacer-
bations as important management targets. Few disease-based models exist for
COPD. Our objective was to develop a dynamic, natural history model that reflects
progression of COPD, events and treatments that characterize its management.
METHODS:We developed an Excel-based Markov model with 4 health states rep-
resenting the Global Burden of Lung Disease (GOLD) disease severity classification.
Within each GOLD stage, we model stable disease with three levels of COPD exac-
erbation. We include 2 health states for end-stage treatments (lung transplant and
lung volume reduction surgery [LVRS]) as well as death. Data to populate progres-
sion comes from published clinical studies and lung function data collected within
the Framingham Heart Study. The model simulates disease progression, severity
and event- and stage specific mortality, exacerbations and quality-adjusted sur-
vival over a lifetime. Cost parameters reflect 2010 US resource use. RESULTS: We
calibratedmodel progression andmortality using data from the 5-year LungHealth
Study. Initiating a cohort simulationwith a 60 year old, 79.2% of the cohort remains
in GOLD stage I and II after 5 years. The simulation produces average annual costs
of $970, $5,700, $13,000, and $13,700for GOLD stages I to IV, respectively. Only a
small fraction (2%) of the cohort progresses to transplant and LVRS. Over 91% of
the cohort survived through the 5-year simulation, with a background mortality
rate for 60-year-olds at almost 1% annually. CONCLUSIONS: A natural history
model of COPD can be useful for estimating disease progression, costs and the
impact of new technologies. Future research is needed to validate the model pre-
dictions.
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OBJECTIVES: To estimate COPD exacerbation incidence rates, related costs, and
predictors among managed care patients treated for chronic bronchitis (CB).
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METHODS: A retrospective analysis of the HealthCore Integrated Research Data-
base (HIRD)was conducted to estimate the incidence, costs, and predictors of COPD
exacerbations. The study population included CB patients aged 40 years with 2
years of continuous enrollment in the HIRD,1 hospitalization/emergency depart-
ment (ED) visit or 2 outpatient visits with CB diagnosis (ICD-9-CM 491.xx) from
January 1, 2004 toMay 31, 2011, and2 pharmacy fills for COPDmedications during
the follow-up year (the first fill served as the index date). Patients with asthma,
cystic fibrosis, respiratory tract cancer, and long-term oral corticosteroid use were
excluded. COPD exacerbations were categorized as severe (hospitalization with
COPD as primary diagnosis) ormoderate (ED visit with a primary COPDdiagnosis or
an oral corticosteroid filled within 7 days of a COPD-related office visit). When
multiple exacerbations occurred within a 14-day window, only one (the most se-
vere, if applicable) was counted. Prevalence, costs, and predictors of exacerbations
were measured. RESULTS: A total of 17,382 treated CB patients met inclusion/
exclusion criteria (50.6% female,mean age 66.711.4 years). During pre-index year,
25% had moderate or severe and 14.3% had severe exacerbations. During the post-
index year, the mean COPD maintenance medication fills number was 7.66.3;
42.6% experienced moderate or severe and 24.7% experienced severe exacerba-
tions. Mean exacerbation-related healthcare costs were $8,219$22,644 per mod-
erate or severe and $18,120$31,592 per severe exacerbation. Incidence of baseline
exacerbation was the best predictor of post-index incidence of exacerbation
(0.2595, p0.0001) and also predicted post-index exacerbation-related costs
(0.0870, p0.0002). CONCLUSIONS: CB individuals’ exacerbation rates remain
high despite treatment with COPD maintenance medications. New treatment
strategies designed to reduce CB exacerbations and associated costs should focus
on patients with high prior-year exacerbation rates.
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OBJECTIVES: To compare cost, outcomes and resource utilization between me-
chanically ventilated and non-ventilated critically ill adults. METHODS: All adult
inpatient discharges ( 21 years) with at least one ICU admission during their
hospital stay were selected from the Premier PerspectiveTM Database 2010. Me-
chanically ventilated (MV) patients were identified using ICD-9 codes (cases). MV
cases were matched (1:1) to controls based on propensity score accounting for
patient demographics (age, gender, race), geographic region, hospital characteris-
tics (urban, teaching, hospital bed size), diseases of Charlson comorbidity index,
elective admission status, medical/surgical stay and major diagnostic categories.
We evaluated outcomes such as discharge disposition, hospital length of stay (LOS)
and costs, ICU LOS and costs, and pharmacy, diagnostic and respiratory therapy
costs. Premier provided projectionweightswere used tomakenational projections.
RESULTS: A total of 530,428 critical care discharges were included in the study.
101,061 (19.1%) were coded for mechanical ventilation. After propensity score
matching, 94,577 cases and controls were studied. MV cases had significantly
higher mortality (30.3% vs. 5.9%) and facility discharge (37.0% vs. 31.7%) compared
to controls. MV cases had significantly higher LOS (12.5 vs. 8.2 days), hospital costs
($38,805 vs. $21,735), ICU LOS (7.2 vs. 3.2 days), ICU costs ($12,363 vs. $5,006), phar-
macy costs ($5,233 vs. $2,451), diagnostic costs ($1,319 vs. $788) and respiratory
therapy costs ($2,881 vs. $831) compared to controls. Projected to national levels,
therewere about 828,000MVhospitalizations resulting in $14.1 billion of additional
hospital costs and 3.6million additional hospital days. CONCLUSIONS:Mechanical
ventilation has a significant clinical and economic impact on the health care sys-
tem. Interventions targeting appropriate reduction in days of acute MV and opti-
mization of hospital resources in the care of MV patients may have economic
implications for the hospital as well as clinical benefits for the MV patient.
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is a serious complication of
mechanical ventilation (MV) and is associatedwith an increased inmortality and in
the intensive care unit (ICU) length of stay (LOS). The increasing prevalence of
Methicillin Resistant Staphylococcus aureus in both hospital and community set-
tings presents substantial higher costs which could be reduced using the most
efficient empiric therapy. The aimof this studywas to assess the cost-effectiveness
(CE) of linezolid against vancomycin as an empiric therapy for VAP patients.
METHODS: The study included a cohort of adult patients with VAP in the ICU and
it used a 12-week time horizon with the aid of a decision-tree model to compare
costs and effectiveness of linezolid (600mg/12 hours) and vancomycin (15mg/Kg 12
hours) (standard of care). Effectivenessmeasures were: clinical success rates, mor-
tality rates, ICU LOS and hospital LOS. The epidemiological datawas collected from
published literature and local costs (2011 US$) were obtained from public hospitals
official databases. Only direct medical costs were considered (LOS, medication
costs, hematologic, gastrointestinal and lab exams). Monte Carlo probabilistic sen-
sitivity analysis (PSA)was developed. RESULTS: Results showed linezolid as amore
effective and less expensive option for VAP adult patients in comparison with
vancomycin. Mortality rate was lower with linezolid (10.13% vs. 15.74%) while clin-
ical success rate was higher with linezolid (64%) against vancomicyn (59.5%). ICU
LOS was 17.4 days for linezolid and 21.26 days for vancomycin. Hospital LOS was
8.44 days for linezolid and 9.43 days for vancomycin. Overall medical costs per
patient were US$35,077.18 with linezolid and US$39,980.57 with vancomycin. CE
analyses showed linezolid as cost-saving (dominant strategy). PSA outcomes sup-
port the robustness of these findings. CONCLUSIONS: The empiric use of linezolid
in UCI for adults with VAP would result in economic and health benefits for the
Dominican Republic’s public environment.
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OBJECTIVES: To perform a cost-effectiveness analysis of Indacaterol for moderate
to severe COPD vs monotherapy treatment with Tiotropium or Salmeterol, both
options available at the Public Health Care System inMéxico.METHODS:AMarkov
model was designed. The model identifies five states for COPD according to FEV1:
low, moderate, severe, very severe, and death; the first four states include the
possibility of having a non-severe or a severe exacerbation. Transition probabilities
were obtained from two randomized control trials: INHANCE and INLIGHT-2which
compare a weighted average of patients receiving Indacaterol 150g and 300g
versus Tiotropium 18g, and Salmeterol 200g, daily. Thirty-nine percent of pa-
tients with Indacaterol moved from severe to moderate state of improvement in
FEV1 at 12 weeks of treatment, compared with 31% of patients on Tiotropium arm.
Cycle duration was 12-week, time horizon 3 years, discount rate 5%. Effectiveness
was evaluated by QALYs using utility values where severity states are related to
FEV1. This data was obtained from pivotal clinical trials, while utilities for each
state and exacerbations from the literature. Direct medical costs include, besides
rutinary treatment, the cost of exacerbations expected in each treatment. The cost
values of them were calculated with the cost list of the Mexican Institute of Social
Security. Drug costs come from public tenders 2011. Probabilistic sensitivity anal-
ysis (PSA) was performed using Monte Carlo technique. RESULTS: Monthly drug
cost of treatment with Tiotropium and Salmeterol is 14.08 and 23.2% higher than
Indacaterol, respectively. The expected three–year average costs and QALYs per
patient with each treatment are: Indacaterol US$1020/2.125; Tiotropium US$1169/
2.11; and Salmeterol US$1159/2.11. Indacaterol is a dominant strategy. PSA shows
robustness in the model. CONCLUSIONS: Indacaterol was a dominant alternative
as it had lower cost and more effectiveness than their comparators. These results
showed that is possible to achieve cost-savings and potential clinical benefits with
Indacaterol.
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OBJECTIVES: Invasive Aspergillosis (IA), a second cause of fungal invasive infec-
tions, is acquired by inhalation of spores. The primary infection is developed in
lungs and it migrates to other structures. Mortality rate is 50% reaching up to 95%
in bonemarrow transplants. The aim of this studywas to assess the cost-effective-
ness (CE) of voriconazole, amphotericine B and caspofungin as first-line treatments
for IA inmunosupressed adult patients in Dominican Republic, from the private
health care’s perspective. METHODS: A cohort of patients with IA study was con-
ducted using a decision-tree model to compare costs and effectiveness of of am-
photericin B IV (15mg/kg/day) (basecase), caspofungin IV (initial dosage 70mg/day,
maintenance dosage 50mg/day), and voriconazole IV (12mg/kg/day). Effectiveness
measures were: clinical success rates, mortality rates, intensive care unit (ICU)
length of stay (LOS) and hospital ward LOS. Themodel used a 12-week time horizon
and only direct medical costs were considered. The epidemiologic data was col-
lected from published literature. Local cost data (expressed in 2011 US$) was re-
trieved from Dominican Republic=s private hospital official databases. Monte Carlo
probabilistic sensitivity analysis (PSA) was constructed. RESULTS: Results showed
voriconazole as the least expensive and most effective option for IA patients. ICU
LOS was 7.59, 9.81, and 9.94 days for voriconazole, amphotericine B, and caspofun-
gin, respectively. Hospital LOS was 15.4 days with voriconazole, 16.4 days with
caspofungin and 16.5 with amphotericine B. Voriconazole obtained the lowest
mortality rate (34.1%) in comparison to amphotericine B (50.9%) and caspofungin
(44.7%). Furthermore, in regards to overall expected costs voriconazole resulted
US$2711.25 and US$6881.05 less expensive than amphotericine B and caspofungin,
respectively. CE analyses showed voriconazole as the cost-saving strategy. PSA
results support these findings. CONCLUSIONS: In the private context of Dominican
Republic, voriconazole resulted as a cost-saving option for treating IA inmunosu-
pressed adult patients.
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OBJECTIVES: Invasive aspergillosis (IA) is amajor infectious complication in inmo-
nusupressed patients. Its incidence ranges from 5 percent to more than 20 percent
A55V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
